Viracta Therapeutics, Inc.
NASDAQ:VIRX
0.17 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Viracta Therapeutics, Inc. |
Symbool | VIRX |
Munteenheid | USD |
Prijs | 0.17 |
Beurswaarde | 6,752,540 |
Dividendpercentage | 0% |
52-weken bereik | 0.13 - 1.31 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark Andrew Rothera |
Website | https://www.viracta.com |
An error occurred while fetching data.
Over Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)